UOC
JAZZ icon

UBS O'Connor’s Jazz Pharmaceuticals JAZZ Stock Holding History

UBS O'Connor’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,014
Closed -$908K – 562
2023
Q3 		$908K Sell
7,014
-7,200
-51% -$959K 0.02% 345
2023
Q2 		$1.76M Sell
14,214
-12,610
-47% -$1.7M 0.04% 322
2023
Q1 		$3.93M Buy
26,824
+1,277
+5% +$189K 0.09% 169
2022
Q4 		$4.07M Sell
25,547
-33,493
-57% -$4.91M 0.08% 243
2022
Q3 		$7.87M Buy
59,040
+6,000
+11% +$912K 0.09% 137
2022
Q2 		$8.28M Buy
53,040
+43,226
+440% +$6.65M 0.09% 129
2022
Q1 		$1.53M Buy
+9,814
New +$1.42M 0.02% 632

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS O'Connor's JAZZ Position: Q4 2023 in Review

UBS O'Connor sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 7,014 shares — an estimated $908K sold.

UBS O'Connor first reported a position in JAZZ in Q1 2022 and held it in 7 quarters. The position peaked at $8.28M in Q2 2022. 500 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

  • UBS O'Connor reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 7,014 Jazz Pharmaceuticals shares in Q4 2023, an estimated $908K.
  • UBS O'Connor first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • UBS O'Connor's Jazz Pharmaceuticals position peaked at $8.28M in Q2 2022.
  • 500 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.